Navigation Links
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc. (NASDAQ: INGN) and the Company's clinical collaborators today reported updated Phase 2 data demonstrating a significant correlation between abnormal p53, tumor responses and increased survival following ADVEXIN(R) therapy in patients with recurrent squamous cell carcinoma of the head and neck. The data (Abstract #6057) were presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

Tumor responses were assessed in 112 patients with recurrent head and neck cancer who received ADVEXIN. Overall, the percentages of patients with tumor responses defined by reductions in bi-dimensional tumor area on CT scan of 50 percent, 25 percent, 10 percent or stable disease for more than 2 treatment cycles were 6 percent, 7 percent, 12 percent and 22 percent, respectively. Median survival for these responder populations were 41, 17, 15 and 10 months, respectively. There was a statistically significant increase in median survival for each of the responder populations compared to the 6 month median survival of the non-responders (p less than 0.0016).

"The 41 month median duration of survival for the patients with a 50 percent or greater reduction in tumor size is very impressive and significantly greater than the six month median survival of non-responders that is typical for patients with recurrent tumors," said John Nemunaitis, M.D., Medical Director, Mary Crowley Medical Research Center. "Our findings are also consistent with a growing body of data that even smaller reductions in tumor size are clinically meaningful and are associated with increased survival."

The presentation also included data demonstrating that the predictive abnormal p53 biomarker was associated with a statistically significant increase in tumor responses to ADVEXIN therapy. A reduction in tumor size was observed in 40 percent of patients wi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... 4, 2011 A team of scientists at Tufts ... single-cell levels designed to detect breast cancer earlier, and ... Innovator Award from the Department of Defense Breast Cancer ... Ph.D. The Innovator Awards provide "individuals who ...
...   Research led by St. Jude Children,s Research Hospital scientists ... that are the workhorses of cells and, in the ... The discovery involves a chemical known as ... proteins have this chemical added to the amino acid ...
Cached Medicine Technology:Fighting Breast Cancer Early, One Cell At A Time 2Fighting Breast Cancer Early, One Cell At A Time 3Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... independent freestanding emergency rooms in the United States, named ... its new Missouri City-Lakes facility. , “We are ... as facility medical director of our new Missouri City-Lakes ... of First Choice Emergency Room. , Dr. Harrison ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in the ... for its maternity wedding outfits. Now, all the company’s ... wedding dresses on its website. , 9Lover.com ... The company’s development manager believes the cheap maternity wedding ... current special offer will last until September 29, 2014. ...
(Date:9/17/2014)... A ball gown is the most ... a full-skirted gown reaching the floor, made of luxurious ... special occasion gown manufacturer and retailer, has delightedly unveiled ... ball gowns are offered at discounted rates. , Most ... Such gowns are typically worn with a stole (a ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 The National ... the Match , a comprehensive analysis of the relationship ... a preferred specialty. The new edition is based ... by specialty for U.S. allopathic medical school senior students ... to be able to provide this new edition of ...
(Date:9/17/2014)... Battle Creek, MI (PRWEB) September 17, 2014 ... Recovery , an open-ended drug and alcohol treatment program ... gives them a solid foundation in recovery they can ... and depression. , “About 20% of Americans who are ... or both,” commented A Forever Recovery’s CEO Per ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com: Ladies Can Be Elegant Enough to Draw Everyone’s Attention by Wearing Trendy Ball Gowns 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3
... to lack a particular protein in the brain have ... they say, for exploring the hereditary causes of deafness ... provides an entry point for gaining new insight into ... the protein, says the team, led by scientists at ...
... ATSI ) is looking forward to its ... of Thoracic Surgeons (STS). The event runs January,28-30, ... one of the year,s,key gatherings of cardiovascular surgeons ... ), ATS Medical continues to broaden its ...
... Rochester,Medical Corporation (Nasdaq: ROCM ) will announce quarterly ... The Company will then,hold a quarterly conference call to ... p.m. central standard time (5:00 p.m. eastern time)., ... be accessed at,Rochester Medical,s website at http://www.rocm.com . ...
... PRINCETON, N.J., Jan. 24 The final ... Care Resources,provides a thorough and candid explanation of ... short on delivering solutions to address,the healthcare system,s ... consensus of the New Jersey Hospital Association, the,state,s ...
... Personalizing ones nutrition for maximum health benefits is becoming ... help health professions learn more about this trend at ... Nutrition" is the theme for the 35th annual Texas ... The event, at the Rudder Tower, is from 8 ...
... on healthy living, healthy aging, healthy ... communities, ... million investment in three initiatives that will help,Silicon Valley become the healthiest ... strides in achieving the goals,of healthy living, healthy aging, and healthy communities ...
Cached Medicine News:Health News:Deafness and seizures result when mysterious protein deleted in mice 2Health News:Deafness and seizures result when mysterious protein deleted in mice 3Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 2Health News:ATS Medical Participating in 44th Annual STS Annual Meeting 3Health News:Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008 2Health News:NJHA: State Report Provides Thorough Examination of Hospital Fiscal Woes 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 2Health News:The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America 3
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... is indicated for the treatment of ... as telangiectasia, rosacea, spider angiomas, cherry ... papulosis nigra and keratoses. Patented ... selection of handpieces maximizes versatility, compact ...
... handpieces, used for endophotocoagulation ... with uncompromised laser treatment ... EndoProbe handpieces are compatible ... green (532 nm), OcuLight ...
Medicine Products: